Comparisons of Outcomes between Eligible and Ineligible Patients with CHADS2 Score≥2
At 4 years, 59% of patients had completed follow-up, and the median follow-up duration was 3.9 years. The cumulative incidence of major bleeding at 4 years in the eligible and ineligible groups was 7.0% and 13.4%, respectively (Figure 2a ). The risk of major bleeding in ineligible patients with CHADS2 score ≥2 was almost double that of eligible patients and statistically significantly higher (Table 4 ). The 4-year cumulative stroke and systemic embolism incidence in the eligible and ineligible groups was 5.5% and 7.5%, respectively (Figure 2b ). Notably, both groups had a CHADS2 score of ≥2; however, the risk of stroke/SE was significantly higher in ineligible patients than in eligible patients (Table 4 ). At 4 years, the cumulative incidence of death from any cause in the eligible and ineligible groups was 7.3% and 17.6%, respectively (Figure 1c ). The risk of death from any cause in ineligible patients was approximately three times higher than that in eligible patients (Table 4 ).